dc.contributor.author
Michelet, Robin
dc.contributor.author
Bindellini, Davide
dc.contributor.author
Melin, Johanna
dc.contributor.author
Neumann, Uta
dc.contributor.author
Blankenstein, Oliver
dc.contributor.author
Huisinga, Wilhelm
dc.contributor.author
Johnson, Trevor N.
dc.contributor.author
Whitaker, Martin J.
dc.contributor.author
Ross, Richard
dc.contributor.author
Kloft, Charlotte
dc.date.accessioned
2023-05-03T09:16:10Z
dc.date.available
2023-05-03T09:16:10Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/39176
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-38893
dc.description.abstract
Introduction: Hydrocortisone is the standard of care in cortisol replacement therapy for congenital adrenal hyperplasia patients. Challenges in mimicking cortisol circadian rhythm and dosing individualization can be overcome by the support of mathematical modelling. Previously, a non-linear mixed-effects (NLME) model was developed based on clinical hydrocortisone pharmacokinetic (PK) pediatric and adult data. Additionally, a physiologically-based pharmacokinetic (PBPK) model was developed for adults and a pediatric model was obtained using maturation functions for relevant processes. In this work, a middle-out approach was applied. The aim was to investigate whether PBPK-derived maturation functions could provide a better description of hydrocortisone PK inter-individual variability when implemented in the NLME framework, with the goal of providing better individual predictions towards precision dosing at the patient level.
Methods: Hydrocortisone PK data from 24 adrenal insufficiency pediatric patients and 30 adult healthy volunteers were used for NLME model development, while the PBPK model and maturation functions of clearance and cortisol binding globulin (CBG) were developed based on previous studies published in the literature.
Results: Clearance (CL) estimates from both approaches were similar for children older than 1 year (CL/F increasing from around 150 L/h to 500 L/h), while CBG concentrations differed across the whole age range (CBGNLME stable around 0.5 μM vs. steady increase from 0.35 to 0.8 μM for CBG PBPK). PBPK-derived maturation functions were subsequently included in the NLME model. After inclusion of the maturation functions, none, a part of, or all parameters were re-estimated. However, the inclusion of CL and/or CBG maturation functions in the NLME model did not result in improved model performance for the CL maturation function (ΔOFV > −15.36) and the re-estimation of parameters using the CBG maturation function most often led to unstable models or individual CL prediction bias.
Discussion: Three explanations for the observed discrepancies could be postulated, i) non-considered maturation of processes such as absorption or first-pass effect, ii) lack of patients between 1 and 12 months, iii) lack of correction of PBPK CL maturation functions derived from urinary concentration ratio data for the renal function relative to adults. These should be investigated in the future to determine how NLME and PBPK methods can work towards deriving insights into pediatric hydrocortisone PK.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
hydrocortisone
en
dc.subject
congenital adrenal hyperplasia
en
dc.subject
population pharmacokinetics
en
dc.subject
middle-out approach
en
dc.subject
physiologically-based pharmacokinetics (PBPK)
en
dc.subject
non-linear mixed effects modelling (NLME)
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.title
Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
1090554
dcterms.bibliographicCitation.doi
10.3389/fphar.2022.1090554
dcterms.bibliographicCitation.journaltitle
Frontiers in Pharmacology
dcterms.bibliographicCitation.originalpublishername
Frontiers Media S.A.
dcterms.bibliographicCitation.volume
13 (2023)
dcterms.bibliographicCitation.url
https://doi.org/10.3389/fphar.2022.1090554
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.note.author
Open Access Funding provided by Freie Universität Berlin.
en
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1663-9812
refubium.resourceType.provider
DeepGreen